small molecule

ZEJULA

NIRAPARIB TOSYLATE

Loss of exclusivityMarch 2038latest FDA-listed patent expiry

CompanyGlaxoSmithKline →View the full company profile on CliffBio

Drug detail

Brand name	ZEJULA
Active ingredient	NIRAPARIB TOSYLATE
Strength	EQ 100MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	March 2017
Marketing status	DISCN

Listed patents

Patent	Expires	Type
11673877	March 2038	product
11091459	March 2038	product
8859562	August 2031	use U-2655
8071623	March 2031	substance, product
8436185	April 2029	substance
8143241	August 2027	use U-2655
8071579	August 2027	use U-2655

Regulatory exclusivity

Code	Expires
ODE-295	April 2027
ODE-277	October 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from GlaxoSmithKline